Overview

A Clinical Trial Evaluating the Efficacy and Safety of HSK21542 in Patients With Chronic Kidney Disease-Associated Pruritus

Status:
Not yet recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
This is a multi-center, randomized, double-blind, placebo-controlled study. About 310 maintenance hemodialysis patients with moderate or above chronic kidney disease-associated pruritus are planned to be enrolled. They will randomized into the treatment group (HSK21542, 0.3 μg/kg) and the control group (placebo) at a 1:1 ratio.
Phase:
Phase 3
Details
Lead Sponsor:
Haisco Pharmaceutical Group Co., Ltd.